XML 55 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Other Balance Sheet Details
 9 Months Ended
Sep. 30, 2024
Other Balance Sheet Details [Abstract]  
Other Balance Sheet Details Other Balance Sheet Details
Inventory consisted of the following:
(in millions)September 30,
2024		December 31,
2023
Raw materials$23.7 $21.5 
Work in process10.6 9.7 
Finished goods11.5 12.3 
45.8 43.5 
Less inventory reserves
— (5.2)
Total inventory
$45.8 $38.3 
Accounts payable and accrued liabilities consisted of the following:
(in millions)September 30,
2024		December 31,
2023
Sales rebates and reserves$138.9 $139.3 
Accrued employee related costs77.1 86.2 
Current branded prescription drug fee42.7 45.7 
Accrued development costs38.3 44.3 
Accounts payable and other accrued liabilities95.7 133.3 
Total accounts payable and accrued liabilities$392.7 $448.8 
Other noncurrent liabilities consisted of the following:
(in millions)September 30,
2024		December 31,
2023
Noncurrent income taxes payable
$134.9 $96.0 
Other noncurrent liabilities
0.1 10.3 
Total other noncurrent liabilities$135.0 $106.3 
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions)September 30,
2024		September 30,
2023
Cash and cash equivalents$349.1 $293.7 
Restricted cash included in other noncurrent assets
8.0 8.0 
Total cash, cash equivalents, and restricted cash$357.1 $301.7